MedPath

Effect of Atrovastatin on lung inflammation in bronchitis

Phase 3
Conditions
Chronic bronchitis.
Chronic bronchitis: obstructive
Registration Number
IRCT138904144312N1
Lead Sponsor
shiraz University Of medical Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
90
Inclusion Criteria

exposure to mustard gas during the Iran-Iraq war and have suffered from chronic bronchitis (history of chronic cough and sputum daily for 3 months during recent 2 years)

Exclusion criteria: Using statin in the last 3 months of study starting time; exacerbation of symptoms in the past 4 weeks; connective tissue disease; sarcoidosis; eosinophilic granuloma; pneumoconiosis; lymphoma; carcinomatous; smokers

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
TNF alpha level. Timepoint: before intervention - 3 month after intervention. Method of measurement: ELISA test is performed.;Interleukin 6 level. Timepoint: before intervention - 3 month after intervention. Method of measurement: ELISA test is performed.;Added at 2015-08-05: Procalcitonin. Timepoint: Added at 2015-08-05: At the beginning of the intervention and 3 months after intervention. Method of measurement: Added at 2015-08-05: ELISA.
Secondary Outcome Measures
NameTimeMethod
Withe blood cell count. Timepoint: before intervention - 3 month after intervention. Method of measurement: Complete Blood Count.;Added at 2015-08-05: hs-CRP. Timepoint: Added at 2015-08-05: At the beginning the intervention and 3 months after intervention. Method of measurement: Added at 2015-08-05: Immunoassay.
© Copyright 2025. All Rights Reserved by MedPath